nodes	percent_of_prediction	percent_of_DWPC	metapath
Sirolimus—MTOR—lung cancer	0.321	0.854	CbGaD
Sirolimus—ABCB1—lung cancer	0.0552	0.147	CbGaD
Sirolimus—SLCO1B1—Irinotecan—lung cancer	0.0207	0.0636	CbGbCtD
Sirolimus—CYP3A5—Gefitinib—lung cancer	0.017	0.0524	CbGbCtD
Sirolimus—CYP3A5—Teniposide—lung cancer	0.0165	0.0509	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.0123	0.0378	CbGbCtD
Sirolimus—CYP3A7—Paclitaxel—lung cancer	0.0123	0.0378	CbGbCtD
Sirolimus—CYP3A7—Irinotecan—lung cancer	0.0121	0.0373	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.0121	0.0373	CbGbCtD
Sirolimus—ABCB1—Topotecan—lung cancer	0.0121	0.0373	CbGbCtD
Sirolimus—ABCB1—Gefitinib—lung cancer	0.0111	0.0341	CbGbCtD
Sirolimus—SLCO1B1—Methotrexate—lung cancer	0.0109	0.0337	CbGbCtD
Sirolimus—CYP3A5—Crizotinib—lung cancer	0.0104	0.0321	CbGbCtD
Sirolimus—CYP3A5—Erlotinib—lung cancer	0.0101	0.031	CbGbCtD
Sirolimus—CYP3A5—Paclitaxel—lung cancer	0.00923	0.0284	CbGbCtD
Sirolimus—CYP3A5—Irinotecan—lung cancer	0.0091	0.028	CbGbCtD
Sirolimus—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.00889	0.0274	CbGbCtD
Sirolimus—CYP3A7—Docetaxel—lung cancer	0.00889	0.0274	CbGbCtD
Sirolimus—ABCB1—Vinorelbine—lung cancer	0.00855	0.0263	CbGbCtD
Sirolimus—CYP3A5—Etoposide—lung cancer	0.00729	0.0224	CbGbCtD
Sirolimus—CYP3A4—Topotecan—lung cancer	0.00727	0.0224	CbGbCtD
Sirolimus—ABCB1—Crizotinib—lung cancer	0.0068	0.0209	CbGbCtD
Sirolimus—CYP3A5—Docetaxel—lung cancer	0.00667	0.0205	CbGbCtD
Sirolimus—CYP3A4—Gefitinib—lung cancer	0.00665	0.0204	CbGbCtD
Sirolimus—ABCB1—Gemcitabine—lung cancer	0.00665	0.0204	CbGbCtD
Sirolimus—ABCB1—Erlotinib—lung cancer	0.00656	0.0202	CbGbCtD
Sirolimus—CYP3A4—Teniposide—lung cancer	0.00645	0.0198	CbGbCtD
Sirolimus—ABCB1—Paclitaxel—lung cancer	0.006	0.0185	CbGbCtD
Sirolimus—ABCB1—Irinotecan—lung cancer	0.00592	0.0182	CbGbCtD
Sirolimus—ABCB1—Vinblastine—lung cancer	0.00527	0.0162	CbGbCtD
Sirolimus—CYP3A4—Vinorelbine—lung cancer	0.00512	0.0158	CbGbCtD
Sirolimus—ABCB1—Cisplatin—lung cancer	0.00483	0.0149	CbGbCtD
Sirolimus—ABCB1—Etoposide—lung cancer	0.00474	0.0146	CbGbCtD
Sirolimus—ABCB1—Docetaxel—lung cancer	0.00434	0.0134	CbGbCtD
Sirolimus—CYP3A4—Crizotinib—lung cancer	0.00407	0.0125	CbGbCtD
Sirolimus—CYP3A4—Erlotinib—lung cancer	0.00393	0.0121	CbGbCtD
Sirolimus—CYP3A4—Paclitaxel—lung cancer	0.0036	0.0111	CbGbCtD
Sirolimus—CYP3A4—Irinotecan—lung cancer	0.00355	0.0109	CbGbCtD
Sirolimus—ABCB1—Doxorubicin—lung cancer	0.00324	0.00996	CbGbCtD
Sirolimus—CYP3A4—Vinblastine—lung cancer	0.00316	0.00971	CbGbCtD
Sirolimus—ABCB1—Methotrexate—lung cancer	0.00313	0.00964	CbGbCtD
Sirolimus—EIF4E—respiratory system—lung cancer	0.00289	0.105	CbGeAlD
Sirolimus—CYP3A4—Etoposide—lung cancer	0.00284	0.00875	CbGbCtD
Sirolimus—FGF2—mammary gland—lung cancer	0.00264	0.0959	CbGeAlD
Sirolimus—CYP3A4—Docetaxel—lung cancer	0.0026	0.008	CbGbCtD
Sirolimus—CYP3A4—Doxorubicin—lung cancer	0.00194	0.00596	CbGbCtD
Sirolimus—MTOR—mammary gland—lung cancer	0.00168	0.0609	CbGeAlD
Sirolimus—EIF4E—lung—lung cancer	0.00153	0.0557	CbGeAlD
Sirolimus—FKBP1A—mammary gland—lung cancer	0.00151	0.0547	CbGeAlD
Sirolimus—FGF2—bronchus—lung cancer	0.00145	0.0526	CbGeAlD
Sirolimus—FGF2—trachea—lung cancer	0.0013	0.0472	CbGeAlD
Sirolimus—SLCO1B1—mammary gland—lung cancer	0.00128	0.0465	CbGeAlD
Sirolimus—Everolimus—MTOR—lung cancer	0.00118	0.278	CrCbGaD
Sirolimus—Pimecrolimus—MTOR—lung cancer	0.00118	0.278	CrCbGaD
Sirolimus—MTOR—respiratory system—lung cancer	0.00112	0.0406	CbGeAlD
Sirolimus—FKBP1A—respiratory system—lung cancer	0.00101	0.0365	CbGeAlD
Sirolimus—FGF2—lung—lung cancer	0.000936	0.0339	CbGeAlD
Sirolimus—MTOR—epithelium—lung cancer	0.000934	0.0339	CbGeAlD
Sirolimus—FKBP1A—epithelium—lung cancer	0.00084	0.0305	CbGeAlD
Sirolimus—FKBP1A—bronchus—lung cancer	0.000828	0.03	CbGeAlD
Sirolimus—Temsirolimus—MTOR—lung cancer	0.000796	0.188	CrCbGaD
Sirolimus—FKBP1A—trachea—lung cancer	0.000743	0.027	CbGeAlD
Sirolimus—Tacrolimus—MTOR—lung cancer	0.000701	0.165	CrCbGaD
Sirolimus—FKBP1A—cardiac atrium—lung cancer	0.000698	0.0253	CbGeAlD
Sirolimus—MTOR—bone marrow—lung cancer	0.000655	0.0238	CbGeAlD
Sirolimus—FGF2—lymph node—lung cancer	0.00064	0.0232	CbGeAlD
Sirolimus—MTOR—lung—lung cancer	0.000594	0.0215	CbGeAlD
Sirolimus—FKBP1A—bone marrow—lung cancer	0.000589	0.0214	CbGeAlD
Sirolimus—FKBP1A—lung—lung cancer	0.000534	0.0194	CbGeAlD
Sirolimus—SLC47A1—lung—lung cancer	0.000459	0.0166	CbGeAlD
Sirolimus—CYP3A5—respiratory system—lung cancer	0.000438	0.0159	CbGeAlD
Sirolimus—MTOR—lymph node—lung cancer	0.000406	0.0147	CbGeAlD
Sirolimus—FKBP1A—lymph node—lung cancer	0.000365	0.0132	CbGeAlD
Sirolimus—SLC47A1—lymph node—lung cancer	0.000314	0.0114	CbGeAlD
Sirolimus—ABCB1—respiratory system—lung cancer	0.000233	0.00844	CbGeAlD
Sirolimus—CYP3A5—lung—lung cancer	0.000233	0.00844	CbGeAlD
Sirolimus—ABCB1—epithelium—lung cancer	0.000194	0.00705	CbGeAlD
Sirolimus—ABCB1—trachea—lung cancer	0.000172	0.00624	CbGeAlD
Sirolimus—Temsirolimus—ABCB1—lung cancer	0.000137	0.0323	CrCbGaD
Sirolimus—ABCB1—bone marrow—lung cancer	0.000136	0.00495	CbGeAlD
Sirolimus—Tacrolimus—ALB—lung cancer	0.000126	0.0298	CrCbGaD
Sirolimus—ABCB1—lung—lung cancer	0.000124	0.00448	CbGeAlD
Sirolimus—Tacrolimus—ABCB1—lung cancer	0.00012	0.0284	CrCbGaD
Sirolimus—ABCB1—lymph node—lung cancer	8.45e-05	0.00306	CbGeAlD
Sirolimus—Chest pain—Docetaxel—lung cancer	3.37e-05	0.000236	CcSEcCtD
Sirolimus—Arthralgia—Docetaxel—lung cancer	3.37e-05	0.000236	CcSEcCtD
Sirolimus—Myalgia—Docetaxel—lung cancer	3.37e-05	0.000236	CcSEcCtD
Sirolimus—Pancytopenia—Doxorubicin—lung cancer	3.37e-05	0.000236	CcSEcCtD
Sirolimus—Nausea—Vinorelbine—lung cancer	3.36e-05	0.000235	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Etoposide—lung cancer	3.35e-05	0.000235	CcSEcCtD
Sirolimus—Dyspepsia—Paclitaxel—lung cancer	3.35e-05	0.000235	CcSEcCtD
Sirolimus—Body temperature increased—Cisplatin—lung cancer	3.35e-05	0.000235	CcSEcCtD
Sirolimus—Asthenia—Irinotecan—lung cancer	3.35e-05	0.000235	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	3.35e-05	0.000234	CcSEcCtD
Sirolimus—Constipation—Etoposide—lung cancer	3.32e-05	0.000233	CcSEcCtD
Sirolimus—Pain—Etoposide—lung cancer	3.32e-05	0.000233	CcSEcCtD
Sirolimus—Dysuria—Doxorubicin—lung cancer	3.31e-05	0.000232	CcSEcCtD
Sirolimus—Neutropenia—Doxorubicin—lung cancer	3.31e-05	0.000232	CcSEcCtD
Sirolimus—Decreased appetite—Paclitaxel—lung cancer	3.31e-05	0.000232	CcSEcCtD
Sirolimus—Upper respiratory tract infection—Doxorubicin—lung cancer	3.29e-05	0.00023	CcSEcCtD
Sirolimus—Haemoglobin—Methotrexate—lung cancer	3.29e-05	0.00023	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Paclitaxel—lung cancer	3.29e-05	0.00023	CcSEcCtD
Sirolimus—Haemorrhage—Methotrexate—lung cancer	3.28e-05	0.000229	CcSEcCtD
Sirolimus—Pollakiuria—Doxorubicin—lung cancer	3.27e-05	0.000229	CcSEcCtD
Sirolimus—Asthenia—Gemcitabine—lung cancer	3.26e-05	0.000228	CcSEcCtD
Sirolimus—Constipation—Paclitaxel—lung cancer	3.26e-05	0.000228	CcSEcCtD
Sirolimus—Pain—Paclitaxel—lung cancer	3.26e-05	0.000228	CcSEcCtD
Sirolimus—Confusional state—Docetaxel—lung cancer	3.26e-05	0.000228	CcSEcCtD
Sirolimus—Pharyngitis—Methotrexate—lung cancer	3.25e-05	0.000228	CcSEcCtD
Sirolimus—Urinary tract disorder—Methotrexate—lung cancer	3.24e-05	0.000226	CcSEcCtD
Sirolimus—Oedema—Docetaxel—lung cancer	3.23e-05	0.000226	CcSEcCtD
Sirolimus—Anaphylactic shock—Docetaxel—lung cancer	3.23e-05	0.000226	CcSEcCtD
Sirolimus—Weight increased—Doxorubicin—lung cancer	3.23e-05	0.000226	CcSEcCtD
Sirolimus—Pruritus—Gemcitabine—lung cancer	3.22e-05	0.000225	CcSEcCtD
Sirolimus—Urethral disorder—Methotrexate—lung cancer	3.21e-05	0.000225	CcSEcCtD
Sirolimus—Infection—Docetaxel—lung cancer	3.21e-05	0.000224	CcSEcCtD
Sirolimus—Weight decreased—Doxorubicin—lung cancer	3.21e-05	0.000224	CcSEcCtD
Sirolimus—Feeling abnormal—Etoposide—lung cancer	3.2e-05	0.000224	CcSEcCtD
Sirolimus—Hyperglycaemia—Doxorubicin—lung cancer	3.2e-05	0.000224	CcSEcCtD
Sirolimus—Diarrhoea—Irinotecan—lung cancer	3.2e-05	0.000224	CcSEcCtD
Sirolimus—Pneumonia—Doxorubicin—lung cancer	3.18e-05	0.000222	CcSEcCtD
Sirolimus—Gastrointestinal pain—Etoposide—lung cancer	3.18e-05	0.000222	CcSEcCtD
Sirolimus—Shock—Docetaxel—lung cancer	3.18e-05	0.000222	CcSEcCtD
Sirolimus—Nervous system disorder—Docetaxel—lung cancer	3.17e-05	0.000222	CcSEcCtD
Sirolimus—Thrombocytopenia—Docetaxel—lung cancer	3.16e-05	0.000221	CcSEcCtD
Sirolimus—Infestation—Doxorubicin—lung cancer	3.16e-05	0.000221	CcSEcCtD
Sirolimus—Infestation NOS—Doxorubicin—lung cancer	3.16e-05	0.000221	CcSEcCtD
Sirolimus—Visual impairment—Methotrexate—lung cancer	3.16e-05	0.000221	CcSEcCtD
Sirolimus—Tachycardia—Docetaxel—lung cancer	3.15e-05	0.000221	CcSEcCtD
Sirolimus—Feeling abnormal—Paclitaxel—lung cancer	3.14e-05	0.00022	CcSEcCtD
Sirolimus—Skin disorder—Docetaxel—lung cancer	3.14e-05	0.000219	CcSEcCtD
Sirolimus—Hypersensitivity—Cisplatin—lung cancer	3.12e-05	0.000219	CcSEcCtD
Sirolimus—Gastrointestinal pain—Paclitaxel—lung cancer	3.12e-05	0.000218	CcSEcCtD
Sirolimus—Diarrhoea—Gemcitabine—lung cancer	3.11e-05	0.000218	CcSEcCtD
Sirolimus—Neuropathy peripheral—Doxorubicin—lung cancer	3.1e-05	0.000217	CcSEcCtD
Sirolimus—Dizziness—Irinotecan—lung cancer	3.09e-05	0.000216	CcSEcCtD
Sirolimus—Stomatitis—Doxorubicin—lung cancer	3.08e-05	0.000216	CcSEcCtD
Sirolimus—Anorexia—Docetaxel—lung cancer	3.08e-05	0.000215	CcSEcCtD
Sirolimus—Abdominal pain—Etoposide—lung cancer	3.07e-05	0.000215	CcSEcCtD
Sirolimus—Body temperature increased—Etoposide—lung cancer	3.07e-05	0.000215	CcSEcCtD
Sirolimus—Urinary tract infection—Doxorubicin—lung cancer	3.07e-05	0.000215	CcSEcCtD
Sirolimus—Conjunctivitis—Doxorubicin—lung cancer	3.07e-05	0.000215	CcSEcCtD
Sirolimus—Tinnitus—Methotrexate—lung cancer	3.05e-05	0.000214	CcSEcCtD
Sirolimus—Asthenia—Cisplatin—lung cancer	3.04e-05	0.000213	CcSEcCtD
Sirolimus—Cardiac disorder—Methotrexate—lung cancer	3.04e-05	0.000213	CcSEcCtD
Sirolimus—Sweating—Doxorubicin—lung cancer	3.03e-05	0.000212	CcSEcCtD
Sirolimus—Hypotension—Docetaxel—lung cancer	3.02e-05	0.000211	CcSEcCtD
Sirolimus—Haematuria—Doxorubicin—lung cancer	3.01e-05	0.000211	CcSEcCtD
Sirolimus—Abdominal pain—Paclitaxel—lung cancer	3.01e-05	0.000211	CcSEcCtD
Sirolimus—Body temperature increased—Paclitaxel—lung cancer	3.01e-05	0.000211	CcSEcCtD
Sirolimus—Hepatobiliary disease—Doxorubicin—lung cancer	2.99e-05	0.000209	CcSEcCtD
Sirolimus—Epistaxis—Doxorubicin—lung cancer	2.98e-05	0.000209	CcSEcCtD
Sirolimus—Angiopathy—Methotrexate—lung cancer	2.97e-05	0.000208	CcSEcCtD
Sirolimus—Vomiting—Irinotecan—lung cancer	2.97e-05	0.000208	CcSEcCtD
Sirolimus—Sinusitis—Doxorubicin—lung cancer	2.96e-05	0.000207	CcSEcCtD
Sirolimus—Immune system disorder—Methotrexate—lung cancer	2.96e-05	0.000207	CcSEcCtD
Sirolimus—Mediastinal disorder—Methotrexate—lung cancer	2.95e-05	0.000207	CcSEcCtD
Sirolimus—Rash—Irinotecan—lung cancer	2.95e-05	0.000206	CcSEcCtD
Sirolimus—Dermatitis—Irinotecan—lung cancer	2.94e-05	0.000206	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Docetaxel—lung cancer	2.94e-05	0.000206	CcSEcCtD
Sirolimus—Chills—Methotrexate—lung cancer	2.94e-05	0.000206	CcSEcCtD
Sirolimus—Headache—Irinotecan—lung cancer	2.93e-05	0.000205	CcSEcCtD
Sirolimus—Insomnia—Docetaxel—lung cancer	2.92e-05	0.000204	CcSEcCtD
Sirolimus—Diarrhoea—Cisplatin—lung cancer	2.9e-05	0.000203	CcSEcCtD
Sirolimus—Paraesthesia—Docetaxel—lung cancer	2.9e-05	0.000203	CcSEcCtD
Sirolimus—Vomiting—Gemcitabine—lung cancer	2.89e-05	0.000202	CcSEcCtD
Sirolimus—Dyspnoea—Docetaxel—lung cancer	2.88e-05	0.000201	CcSEcCtD
Sirolimus—Somnolence—Docetaxel—lung cancer	2.87e-05	0.000201	CcSEcCtD
Sirolimus—Rash—Gemcitabine—lung cancer	2.87e-05	0.000201	CcSEcCtD
Sirolimus—Dermatitis—Gemcitabine—lung cancer	2.87e-05	0.000201	CcSEcCtD
Sirolimus—Hypersensitivity—Etoposide—lung cancer	2.86e-05	0.0002	CcSEcCtD
Sirolimus—Malnutrition—Methotrexate—lung cancer	2.85e-05	0.0002	CcSEcCtD
Sirolimus—Haemoglobin—Doxorubicin—lung cancer	2.85e-05	0.0002	CcSEcCtD
Sirolimus—Headache—Gemcitabine—lung cancer	2.85e-05	0.000199	CcSEcCtD
Sirolimus—Rhinitis—Doxorubicin—lung cancer	2.84e-05	0.000199	CcSEcCtD
Sirolimus—Dyspepsia—Docetaxel—lung cancer	2.84e-05	0.000199	CcSEcCtD
Sirolimus—Haemorrhage—Doxorubicin—lung cancer	2.84e-05	0.000198	CcSEcCtD
Sirolimus—Hypoaesthesia—Doxorubicin—lung cancer	2.82e-05	0.000197	CcSEcCtD
Sirolimus—Pharyngitis—Doxorubicin—lung cancer	2.82e-05	0.000197	CcSEcCtD
Sirolimus—Decreased appetite—Docetaxel—lung cancer	2.81e-05	0.000196	CcSEcCtD
Sirolimus—Hypersensitivity—Paclitaxel—lung cancer	2.81e-05	0.000196	CcSEcCtD
Sirolimus—Urinary tract disorder—Doxorubicin—lung cancer	2.8e-05	0.000196	CcSEcCtD
Sirolimus—Oedema peripheral—Doxorubicin—lung cancer	2.79e-05	0.000196	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Docetaxel—lung cancer	2.79e-05	0.000195	CcSEcCtD
Sirolimus—Asthenia—Etoposide—lung cancer	2.79e-05	0.000195	CcSEcCtD
Sirolimus—Connective tissue disorder—Doxorubicin—lung cancer	2.79e-05	0.000195	CcSEcCtD
Sirolimus—Urethral disorder—Doxorubicin—lung cancer	2.78e-05	0.000195	CcSEcCtD
Sirolimus—Nausea—Irinotecan—lung cancer	2.77e-05	0.000194	CcSEcCtD
Sirolimus—Pain—Docetaxel—lung cancer	2.76e-05	0.000193	CcSEcCtD
Sirolimus—Constipation—Docetaxel—lung cancer	2.76e-05	0.000193	CcSEcCtD
Sirolimus—Back pain—Methotrexate—lung cancer	2.76e-05	0.000193	CcSEcCtD
Sirolimus—Pruritus—Etoposide—lung cancer	2.75e-05	0.000192	CcSEcCtD
Sirolimus—Visual impairment—Doxorubicin—lung cancer	2.73e-05	0.000191	CcSEcCtD
Sirolimus—Asthenia—Paclitaxel—lung cancer	2.73e-05	0.000191	CcSEcCtD
Sirolimus—Nausea—Gemcitabine—lung cancer	2.7e-05	0.000189	CcSEcCtD
Sirolimus—Vomiting—Cisplatin—lung cancer	2.7e-05	0.000189	CcSEcCtD
Sirolimus—Pruritus—Paclitaxel—lung cancer	2.7e-05	0.000189	CcSEcCtD
Sirolimus—Rash—Cisplatin—lung cancer	2.67e-05	0.000187	CcSEcCtD
Sirolimus—Dermatitis—Cisplatin—lung cancer	2.67e-05	0.000187	CcSEcCtD
Sirolimus—Feeling abnormal—Docetaxel—lung cancer	2.66e-05	0.000186	CcSEcCtD
Sirolimus—Diarrhoea—Etoposide—lung cancer	2.66e-05	0.000186	CcSEcCtD
Sirolimus—Ill-defined disorder—Methotrexate—lung cancer	2.65e-05	0.000185	CcSEcCtD
Sirolimus—Tinnitus—Doxorubicin—lung cancer	2.64e-05	0.000185	CcSEcCtD
Sirolimus—Gastrointestinal pain—Docetaxel—lung cancer	2.64e-05	0.000185	CcSEcCtD
Sirolimus—Anaemia—Methotrexate—lung cancer	2.64e-05	0.000184	CcSEcCtD
Sirolimus—Cardiac disorder—Doxorubicin—lung cancer	2.63e-05	0.000184	CcSEcCtD
Sirolimus—Diarrhoea—Paclitaxel—lung cancer	2.61e-05	0.000182	CcSEcCtD
Sirolimus—Angiopathy—Doxorubicin—lung cancer	2.57e-05	0.00018	CcSEcCtD
Sirolimus—Malaise—Methotrexate—lung cancer	2.57e-05	0.00018	CcSEcCtD
Sirolimus—Dizziness—Etoposide—lung cancer	2.57e-05	0.00018	CcSEcCtD
Sirolimus—Immune system disorder—Doxorubicin—lung cancer	2.56e-05	0.000179	CcSEcCtD
Sirolimus—Mediastinal disorder—Doxorubicin—lung cancer	2.56e-05	0.000179	CcSEcCtD
Sirolimus—Abdominal pain—Docetaxel—lung cancer	2.55e-05	0.000179	CcSEcCtD
Sirolimus—Body temperature increased—Docetaxel—lung cancer	2.55e-05	0.000179	CcSEcCtD
Sirolimus—Leukopenia—Methotrexate—lung cancer	2.55e-05	0.000179	CcSEcCtD
Sirolimus—Chills—Doxorubicin—lung cancer	2.55e-05	0.000178	CcSEcCtD
Sirolimus—Dizziness—Paclitaxel—lung cancer	2.52e-05	0.000176	CcSEcCtD
Sirolimus—Nausea—Cisplatin—lung cancer	2.52e-05	0.000176	CcSEcCtD
Sirolimus—Cough—Methotrexate—lung cancer	2.49e-05	0.000174	CcSEcCtD
Sirolimus—Vomiting—Etoposide—lung cancer	2.47e-05	0.000173	CcSEcCtD
Sirolimus—Malnutrition—Doxorubicin—lung cancer	2.47e-05	0.000173	CcSEcCtD
Sirolimus—Rash—Etoposide—lung cancer	2.45e-05	0.000171	CcSEcCtD
Sirolimus—Dermatitis—Etoposide—lung cancer	2.45e-05	0.000171	CcSEcCtD
Sirolimus—Headache—Etoposide—lung cancer	2.43e-05	0.00017	CcSEcCtD
Sirolimus—Flatulence—Doxorubicin—lung cancer	2.43e-05	0.00017	CcSEcCtD
Sirolimus—Chest pain—Methotrexate—lung cancer	2.43e-05	0.00017	CcSEcCtD
Sirolimus—Arthralgia—Methotrexate—lung cancer	2.43e-05	0.00017	CcSEcCtD
Sirolimus—Myalgia—Methotrexate—lung cancer	2.43e-05	0.00017	CcSEcCtD
Sirolimus—Tension—Doxorubicin—lung cancer	2.42e-05	0.00017	CcSEcCtD
Sirolimus—Vomiting—Paclitaxel—lung cancer	2.42e-05	0.00017	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	2.41e-05	0.000169	CcSEcCtD
Sirolimus—Rash—Paclitaxel—lung cancer	2.4e-05	0.000168	CcSEcCtD
Sirolimus—Dermatitis—Paclitaxel—lung cancer	2.4e-05	0.000168	CcSEcCtD
Sirolimus—Discomfort—Methotrexate—lung cancer	2.4e-05	0.000168	CcSEcCtD
Sirolimus—Nervousness—Doxorubicin—lung cancer	2.4e-05	0.000168	CcSEcCtD
Sirolimus—Back pain—Doxorubicin—lung cancer	2.39e-05	0.000167	CcSEcCtD
Sirolimus—Headache—Paclitaxel—lung cancer	2.39e-05	0.000167	CcSEcCtD
Sirolimus—Hypersensitivity—Docetaxel—lung cancer	2.38e-05	0.000166	CcSEcCtD
Sirolimus—Muscle spasms—Doxorubicin—lung cancer	2.37e-05	0.000166	CcSEcCtD
Sirolimus—Confusional state—Methotrexate—lung cancer	2.35e-05	0.000164	CcSEcCtD
Sirolimus—Anaphylactic shock—Methotrexate—lung cancer	2.33e-05	0.000163	CcSEcCtD
Sirolimus—Asthenia—Docetaxel—lung cancer	2.32e-05	0.000162	CcSEcCtD
Sirolimus—Infection—Methotrexate—lung cancer	2.31e-05	0.000162	CcSEcCtD
Sirolimus—Nausea—Etoposide—lung cancer	2.31e-05	0.000162	CcSEcCtD
Sirolimus—Ill-defined disorder—Doxorubicin—lung cancer	2.29e-05	0.00016	CcSEcCtD
Sirolimus—Pruritus—Docetaxel—lung cancer	2.28e-05	0.00016	CcSEcCtD
Sirolimus—Nervous system disorder—Methotrexate—lung cancer	2.28e-05	0.00016	CcSEcCtD
Sirolimus—Anaemia—Doxorubicin—lung cancer	2.28e-05	0.00016	CcSEcCtD
Sirolimus—Thrombocytopenia—Methotrexate—lung cancer	2.28e-05	0.000159	CcSEcCtD
Sirolimus—Agitation—Doxorubicin—lung cancer	2.27e-05	0.000159	CcSEcCtD
Sirolimus—Nausea—Paclitaxel—lung cancer	2.26e-05	0.000158	CcSEcCtD
Sirolimus—Skin disorder—Methotrexate—lung cancer	2.26e-05	0.000158	CcSEcCtD
Sirolimus—Hyperhidrosis—Methotrexate—lung cancer	2.25e-05	0.000157	CcSEcCtD
Sirolimus—Malaise—Doxorubicin—lung cancer	2.23e-05	0.000156	CcSEcCtD
Sirolimus—Anorexia—Methotrexate—lung cancer	2.22e-05	0.000155	CcSEcCtD
Sirolimus—Syncope—Doxorubicin—lung cancer	2.21e-05	0.000155	CcSEcCtD
Sirolimus—Leukopenia—Doxorubicin—lung cancer	2.21e-05	0.000155	CcSEcCtD
Sirolimus—Diarrhoea—Docetaxel—lung cancer	2.21e-05	0.000155	CcSEcCtD
Sirolimus—Palpitations—Doxorubicin—lung cancer	2.18e-05	0.000153	CcSEcCtD
Sirolimus—Hypotension—Methotrexate—lung cancer	2.17e-05	0.000152	CcSEcCtD
Sirolimus—Loss of consciousness—Doxorubicin—lung cancer	2.17e-05	0.000152	CcSEcCtD
Sirolimus—Cough—Doxorubicin—lung cancer	2.15e-05	0.000151	CcSEcCtD
Sirolimus—Dizziness—Docetaxel—lung cancer	2.14e-05	0.000149	CcSEcCtD
Sirolimus—Hypertension—Doxorubicin—lung cancer	2.13e-05	0.000149	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Methotrexate—lung cancer	2.12e-05	0.000148	CcSEcCtD
Sirolimus—Insomnia—Methotrexate—lung cancer	2.11e-05	0.000147	CcSEcCtD
Sirolimus—Chest pain—Doxorubicin—lung cancer	2.1e-05	0.000147	CcSEcCtD
Sirolimus—Arthralgia—Doxorubicin—lung cancer	2.1e-05	0.000147	CcSEcCtD
Sirolimus—Myalgia—Doxorubicin—lung cancer	2.1e-05	0.000147	CcSEcCtD
Sirolimus—Anxiety—Doxorubicin—lung cancer	2.1e-05	0.000147	CcSEcCtD
Sirolimus—Paraesthesia—Methotrexate—lung cancer	2.09e-05	0.000146	CcSEcCtD
Sirolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	2.09e-05	0.000146	CcSEcCtD
Sirolimus—Discomfort—Doxorubicin—lung cancer	2.08e-05	0.000145	CcSEcCtD
Sirolimus—Dyspnoea—Methotrexate—lung cancer	2.08e-05	0.000145	CcSEcCtD
Sirolimus—Somnolence—Methotrexate—lung cancer	2.07e-05	0.000145	CcSEcCtD
Sirolimus—Vomiting—Docetaxel—lung cancer	2.05e-05	0.000144	CcSEcCtD
Sirolimus—Dyspepsia—Methotrexate—lung cancer	2.05e-05	0.000143	CcSEcCtD
Sirolimus—Rash—Docetaxel—lung cancer	2.04e-05	0.000142	CcSEcCtD
Sirolimus—Dermatitis—Docetaxel—lung cancer	2.03e-05	0.000142	CcSEcCtD
Sirolimus—Confusional state—Doxorubicin—lung cancer	2.03e-05	0.000142	CcSEcCtD
Sirolimus—Decreased appetite—Methotrexate—lung cancer	2.02e-05	0.000142	CcSEcCtD
Sirolimus—Headache—Docetaxel—lung cancer	2.02e-05	0.000142	CcSEcCtD
Sirolimus—Oedema—Doxorubicin—lung cancer	2.02e-05	0.000141	CcSEcCtD
Sirolimus—Anaphylactic shock—Doxorubicin—lung cancer	2.02e-05	0.000141	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Methotrexate—lung cancer	2.01e-05	0.000141	CcSEcCtD
Sirolimus—Infection—Doxorubicin—lung cancer	2e-05	0.00014	CcSEcCtD
Sirolimus—Pain—Methotrexate—lung cancer	1.99e-05	0.000139	CcSEcCtD
Sirolimus—Shock—Doxorubicin—lung cancer	1.98e-05	0.000139	CcSEcCtD
Sirolimus—Nervous system disorder—Doxorubicin—lung cancer	1.98e-05	0.000138	CcSEcCtD
Sirolimus—Thrombocytopenia—Doxorubicin—lung cancer	1.97e-05	0.000138	CcSEcCtD
Sirolimus—Tachycardia—Doxorubicin—lung cancer	1.97e-05	0.000138	CcSEcCtD
Sirolimus—Skin disorder—Doxorubicin—lung cancer	1.96e-05	0.000137	CcSEcCtD
Sirolimus—Hyperhidrosis—Doxorubicin—lung cancer	1.95e-05	0.000136	CcSEcCtD
Sirolimus—Anorexia—Doxorubicin—lung cancer	1.92e-05	0.000134	CcSEcCtD
Sirolimus—Nausea—Docetaxel—lung cancer	1.92e-05	0.000134	CcSEcCtD
Sirolimus—Feeling abnormal—Methotrexate—lung cancer	1.92e-05	0.000134	CcSEcCtD
Sirolimus—Gastrointestinal pain—Methotrexate—lung cancer	1.9e-05	0.000133	CcSEcCtD
Sirolimus—Hypotension—Doxorubicin—lung cancer	1.88e-05	0.000132	CcSEcCtD
Sirolimus—Abdominal pain—Methotrexate—lung cancer	1.84e-05	0.000129	CcSEcCtD
Sirolimus—Body temperature increased—Methotrexate—lung cancer	1.84e-05	0.000129	CcSEcCtD
Sirolimus—Musculoskeletal discomfort—Doxorubicin—lung cancer	1.84e-05	0.000128	CcSEcCtD
Sirolimus—Insomnia—Doxorubicin—lung cancer	1.82e-05	0.000128	CcSEcCtD
Sirolimus—Paraesthesia—Doxorubicin—lung cancer	1.81e-05	0.000127	CcSEcCtD
Sirolimus—Dyspnoea—Doxorubicin—lung cancer	1.8e-05	0.000126	CcSEcCtD
Sirolimus—Somnolence—Doxorubicin—lung cancer	1.79e-05	0.000125	CcSEcCtD
Sirolimus—Dyspepsia—Doxorubicin—lung cancer	1.77e-05	0.000124	CcSEcCtD
Sirolimus—Decreased appetite—Doxorubicin—lung cancer	1.75e-05	0.000123	CcSEcCtD
Sirolimus—Gastrointestinal disorder—Doxorubicin—lung cancer	1.74e-05	0.000122	CcSEcCtD
Sirolimus—Pain—Doxorubicin—lung cancer	1.72e-05	0.000121	CcSEcCtD
Sirolimus—Constipation—Doxorubicin—lung cancer	1.72e-05	0.000121	CcSEcCtD
Sirolimus—Hypersensitivity—Methotrexate—lung cancer	1.71e-05	0.00012	CcSEcCtD
Sirolimus—Asthenia—Methotrexate—lung cancer	1.67e-05	0.000117	CcSEcCtD
Sirolimus—Feeling abnormal—Doxorubicin—lung cancer	1.66e-05	0.000116	CcSEcCtD
Sirolimus—Gastrointestinal pain—Doxorubicin—lung cancer	1.65e-05	0.000115	CcSEcCtD
Sirolimus—Pruritus—Methotrexate—lung cancer	1.65e-05	0.000115	CcSEcCtD
Sirolimus—Body temperature increased—Doxorubicin—lung cancer	1.59e-05	0.000111	CcSEcCtD
Sirolimus—Abdominal pain—Doxorubicin—lung cancer	1.59e-05	0.000111	CcSEcCtD
Sirolimus—Diarrhoea—Methotrexate—lung cancer	1.59e-05	0.000111	CcSEcCtD
Sirolimus—Dizziness—Methotrexate—lung cancer	1.54e-05	0.000108	CcSEcCtD
Sirolimus—Hypersensitivity—Doxorubicin—lung cancer	1.48e-05	0.000104	CcSEcCtD
Sirolimus—Vomiting—Methotrexate—lung cancer	1.48e-05	0.000104	CcSEcCtD
Sirolimus—Rash—Methotrexate—lung cancer	1.47e-05	0.000103	CcSEcCtD
Sirolimus—Dermatitis—Methotrexate—lung cancer	1.47e-05	0.000103	CcSEcCtD
Sirolimus—Headache—Methotrexate—lung cancer	1.46e-05	0.000102	CcSEcCtD
Sirolimus—Asthenia—Doxorubicin—lung cancer	1.45e-05	0.000101	CcSEcCtD
Sirolimus—Pruritus—Doxorubicin—lung cancer	1.43e-05	9.98e-05	CcSEcCtD
Sirolimus—Nausea—Methotrexate—lung cancer	1.38e-05	9.67e-05	CcSEcCtD
Sirolimus—Diarrhoea—Doxorubicin—lung cancer	1.38e-05	9.65e-05	CcSEcCtD
Sirolimus—Dizziness—Doxorubicin—lung cancer	1.33e-05	9.33e-05	CcSEcCtD
Sirolimus—Vomiting—Doxorubicin—lung cancer	1.28e-05	8.97e-05	CcSEcCtD
Sirolimus—Rash—Doxorubicin—lung cancer	1.27e-05	8.89e-05	CcSEcCtD
Sirolimus—Dermatitis—Doxorubicin—lung cancer	1.27e-05	8.88e-05	CcSEcCtD
Sirolimus—Headache—Doxorubicin—lung cancer	1.26e-05	8.83e-05	CcSEcCtD
Sirolimus—Nausea—Doxorubicin—lung cancer	1.2e-05	8.38e-05	CcSEcCtD
Sirolimus—MTOR—Adaptive Immune System—HRAS—lung cancer	2.95e-06	2.38e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—IL6—lung cancer	2.94e-06	2.37e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—HRAS—lung cancer	2.94e-06	2.37e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—TP53—lung cancer	2.93e-06	2.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APOA1—lung cancer	2.93e-06	2.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CB—lung cancer	2.93e-06	2.36e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CD4—lung cancer	2.93e-06	2.36e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—SRC—lung cancer	2.92e-06	2.36e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MAPK3—lung cancer	2.92e-06	2.35e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTT1—lung cancer	2.92e-06	2.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL2—lung cancer	2.92e-06	2.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KDR—lung cancer	2.91e-06	2.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTGS2—lung cancer	2.9e-06	2.34e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—STK11—lung cancer	2.89e-06	2.33e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.89e-06	2.33e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2A6—lung cancer	2.88e-06	2.32e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GCLC—lung cancer	2.88e-06	2.32e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—VEGFA—lung cancer	2.85e-06	2.3e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MDM2—lung cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—KRAS—lung cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—MYC—lung cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—JUN—lung cancer	2.84e-06	2.29e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—RAF1—lung cancer	2.83e-06	2.28e-05	CbGpPWpGaD
Sirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	2.83e-06	2.28e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—STAT3—lung cancer	2.82e-06	2.27e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—NRAS—lung cancer	2.81e-06	2.27e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—IL6—lung cancer	2.81e-06	2.27e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—HRAS—lung cancer	2.81e-06	2.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—ERBB2—lung cancer	2.8e-06	2.26e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—EGFR—lung cancer	2.77e-06	2.24e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—APOA1—lung cancer	2.77e-06	2.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MTOR—lung cancer	2.77e-06	2.23e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CB—lung cancer	2.77e-06	2.23e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CG—lung cancer	2.75e-06	2.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—CDKN1A—lung cancer	2.75e-06	2.22e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PTEN—lung cancer	2.74e-06	2.21e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ENO1—lung cancer	2.73e-06	2.2e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	2.73e-06	2.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—RRM1—lung cancer	2.72e-06	2.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA3—lung cancer	2.72e-06	2.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Innate Immune System—AKT1—lung cancer	2.71e-06	2.19e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MAPK3—lung cancer	2.69e-06	2.17e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—IL6—lung cancer	2.69e-06	2.17e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CG—lung cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—APC—lung cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KIT—lung cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTP1—lung cancer	2.68e-06	2.16e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CXCL8—lung cancer	2.66e-06	2.14e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGF—lung cancer	2.65e-06	2.14e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—POMC—lung cancer	2.62e-06	2.11e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—MYC—lung cancer	2.62e-06	2.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—KRAS—lung cancer	2.62e-06	2.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EP300—lung cancer	2.62e-06	2.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—PIK3CA—lung cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Sirolimus—MTOR—Adaptive Immune System—AKT1—lung cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CAT—lung cancer	2.61e-06	2.1e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Disease—AKT1—lung cancer	2.6e-06	2.09e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—EGFR—lung cancer	2.56e-06	2.07e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—B4GALT5—lung cancer	2.56e-06	2.07e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	2.56e-06	2.06e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—CREBBP—lung cancer	2.55e-06	2.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—POMC—lung cancer	2.55e-06	2.06e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—SRC—lung cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CASP3—lung cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL2—lung cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—CDKN1A—lung cancer	2.54e-06	2.05e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ABCB1—lung cancer	2.54e-06	2.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PTEN—lung cancer	2.53e-06	2.04e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CG—lung cancer	2.53e-06	2.04e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—BRAF—lung cancer	2.52e-06	2.03e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA4—lung cancer	2.49e-06	2.01e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—TYMS—lung cancer	2.49e-06	2.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6R—lung cancer	2.49e-06	2.01e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CREBBP—lung cancer	2.48e-06	2e-05	CbGpPWpGaD
Sirolimus—EIF4E—Signaling Pathways—AKT1—lung cancer	2.48e-06	2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CCND1—lung cancer	2.48e-06	2e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—JUN—lung cancer	2.47e-06	1.99e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—GSTM1—lung cancer	2.46e-06	1.99e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—STAT3—lung cancer	2.45e-06	1.98e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP2E1—lung cancer	2.45e-06	1.98e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—NRAS—lung cancer	2.45e-06	1.97e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA2—lung cancer	2.43e-06	1.96e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—NQO1—lung cancer	2.42e-06	1.95e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CD—lung cancer	2.42e-06	1.95e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—KRAS—lung cancer	2.42e-06	1.95e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EP300—lung cancer	2.42e-06	1.95e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—HRAS—lung cancer	2.41e-06	1.95e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—PIK3CA—lung cancer	2.41e-06	1.94e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—POMC—lung cancer	2.41e-06	1.94e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MMP9—lung cancer	2.4e-06	1.94e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—CDKN1A—lung cancer	2.4e-06	1.93e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—ALB—lung cancer	2.39e-06	1.93e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PTEN—lung cancer	2.39e-06	1.93e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAP2K1—lung cancer	2.37e-06	1.91e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CD—lung cancer	2.35e-06	1.9e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—SRC—lung cancer	2.35e-06	1.89e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—CREBBP—lung cancer	2.34e-06	1.89e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—MAPK3—lung cancer	2.34e-06	1.89e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTA1—lung cancer	2.34e-06	1.89e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CYP1A1—lung cancer	2.33e-06	1.88e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCC3—lung cancer	2.32e-06	1.87e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ERCC2—lung cancer	2.31e-06	1.87e-05	CbGpPWpGaD
Sirolimus—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	2.31e-06	1.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—IL6—lung cancer	2.31e-06	1.86e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EP300—lung cancer	2.28e-06	1.84e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—STAT3—lung cancer	2.27e-06	1.83e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—NRAS—lung cancer	2.26e-06	1.82e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKR1C1—lung cancer	2.24e-06	1.81e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—EGFR—lung cancer	2.23e-06	1.8e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—HRAS—lung cancer	2.23e-06	1.8e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—PIK3CA—lung cancer	2.22e-06	1.79e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CD—lung cancer	2.22e-06	1.79e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—SRC—lung cancer	2.22e-06	1.79e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—ALB—lung cancer	2.19e-06	1.77e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—STK11—lung cancer	2.18e-06	1.76e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—UGT1A1—lung cancer	2.18e-06	1.76e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MAPK3—lung cancer	2.16e-06	1.75e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—VEGFA—lung cancer	2.16e-06	1.74e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—TP53—lung cancer	2.15e-06	1.74e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—STAT3—lung cancer	2.14e-06	1.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—NRAS—lung cancer	2.13e-06	1.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—IL6—lung cancer	2.13e-06	1.72e-05	CbGpPWpGaD
Sirolimus—FGF2—Immune System—AKT1—lung cancer	2.13e-06	1.72e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CB—lung cancer	2.11e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MDM2—lung cancer	2.11e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—KRAS—lung cancer	2.11e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—MYC—lung cancer	2.1e-06	1.7e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—RAF1—lung cancer	2.1e-06	1.7e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GNG11—lung cancer	2.1e-06	1.69e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTGS2—lung cancer	2.09e-06	1.69e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—ERBB2—lung cancer	2.08e-06	1.68e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—EGFR—lung cancer	2.06e-06	1.66e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—HRAS—lung cancer	2.06e-06	1.66e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CB—lung cancer	2.05e-06	1.66e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MAPK3—lung cancer	2.04e-06	1.65e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTP1—lung cancer	2.02e-06	1.63e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—APOA1—lung cancer	2e-06	1.61e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALDOA—lung cancer	2e-06	1.61e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—MYC—lung cancer	1.99e-06	1.6e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CXCL8—lung cancer	1.97e-06	1.59e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—IL6—lung cancer	1.97e-06	1.59e-05	CbGpPWpGaD
Sirolimus—FGF2—Disease—AKT1—lung cancer	1.97e-06	1.59e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CAT—lung cancer	1.97e-06	1.59e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—KRAS—lung cancer	1.94e-06	1.57e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—EGFR—lung cancer	1.94e-06	1.57e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NCOA3—lung cancer	1.94e-06	1.57e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CB—lung cancer	1.94e-06	1.56e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—PIK3CA—lung cancer	1.94e-06	1.56e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTGS2—lung cancer	1.92e-06	1.55e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ADCY1—lung cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCG2—lung cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CASP3—lung cancer	1.89e-06	1.52e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL2—lung cancer	1.88e-06	1.52e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—TYMS—lung cancer	1.88e-06	1.52e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—GSTM1—lung cancer	1.86e-06	1.5e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—HPGDS—lung cancer	1.85e-06	1.49e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO2—lung cancer	1.85e-06	1.49e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CCND1—lung cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—KRAS—lung cancer	1.84e-06	1.48e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—JUN—lung cancer	1.83e-06	1.48e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CG—lung cancer	1.83e-06	1.47e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PTEN—lung cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Sirolimus—FKBP1A—Signaling Pathways—AKT1—lung cancer	1.82e-06	1.47e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTT1—lung cancer	1.8e-06	1.45e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—HRAS—lung cancer	1.79e-06	1.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—PIK3CA—lung cancer	1.79e-06	1.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MMP9—lung cancer	1.78e-06	1.44e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—CDKN1A—lung cancer	1.78e-06	1.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2A6—lung cancer	1.78e-06	1.43e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GCLC—lung cancer	1.78e-06	1.43e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PTEN—lung cancer	1.77e-06	1.43e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CYP1A1—lung cancer	1.76e-06	1.42e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ERCC2—lung cancer	1.75e-06	1.41e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—POMC—lung cancer	1.74e-06	1.4e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—EP300—lung cancer	1.74e-06	1.4e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—IL6—lung cancer	1.71e-06	1.38e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—CREBBP—lung cancer	1.69e-06	1.37e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EP300—lung cancer	1.69e-06	1.36e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—PIK3CA—lung cancer	1.69e-06	1.36e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ENO1—lung cancer	1.68e-06	1.36e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PTEN—lung cancer	1.67e-06	1.35e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—HRAS—lung cancer	1.65e-06	1.33e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—SRC—lung cancer	1.64e-06	1.33e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—TP53—lung cancer	1.63e-06	1.32e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CD—lung cancer	1.61e-06	1.3e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—VEGFA—lung cancer	1.6e-06	1.29e-05	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—EP300—lung cancer	1.6e-06	1.29e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—STAT3—lung cancer	1.59e-06	1.28e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—ALB—lung cancer	1.59e-06	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—NRAS—lung cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—IL6—lung cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Sirolimus—MTOR—Immune System—AKT1—lung cancer	1.58e-06	1.28e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—HRAS—lung cancer	1.56e-06	1.26e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MAPK3—lung cancer	1.52e-06	1.22e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—APOA1—lung cancer	1.51e-06	1.22e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP2E1—lung cancer	1.51e-06	1.22e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—IL6—lung cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—NQO1—lung cancer	1.49e-06	1.2e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—MYC—lung cancer	1.47e-06	1.19e-05	CbGpPWpGaD
Sirolimus—MTOR—Disease—AKT1—lung cancer	1.46e-06	1.18e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—EGFR—lung cancer	1.44e-06	1.16e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CB—lung cancer	1.4e-06	1.13e-05	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTGS2—lung cancer	1.39e-06	1.12e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CG—lung cancer	1.38e-06	1.11e-05	CbGpPWpGaD
Sirolimus—FGF2—Signaling Pathways—AKT1—lung cancer	1.38e-06	1.11e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—KRAS—lung cancer	1.36e-06	1.1e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—STK11—lung cancer	1.35e-06	1.09e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—POMC—lung cancer	1.31e-06	1.06e-05	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—PIK3CA—lung cancer	1.29e-06	1.04e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—CREBBP—lung cancer	1.28e-06	1.03e-05	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—PIK3CA—lung cancer	1.25e-06	1.01e-05	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTP1—lung cancer	1.25e-06	1e-05	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CD—lung cancer	1.21e-06	9.78e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CAT—lung cancer	1.21e-06	9.77e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—TP53—lung cancer	1.21e-06	9.76e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PTEN—lung cancer	1.21e-06	9.76e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—ALB—lung cancer	1.2e-06	9.65e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—PIK3CA—lung cancer	1.18e-06	9.53e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ABCB1—lung cancer	1.18e-06	9.51e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—TYMS—lung cancer	1.16e-06	9.34e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—HRAS—lung cancer	1.16e-06	9.34e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—EP300—lung cancer	1.15e-06	9.31e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—GSTM1—lung cancer	1.14e-06	9.23e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—IL6—lung cancer	1.11e-06	8.94e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CYP1A1—lung cancer	1.08e-06	8.75e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ERCC2—lung cancer	1.08e-06	8.68e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CB—lung cancer	1.06e-06	8.52e-06	CbGpPWpGaD
Sirolimus—SLCO1B1—Metabolism—AKT1—lung cancer	1.05e-06	8.48e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTGS2—lung cancer	1.05e-06	8.45e-06	CbGpPWpGaD
Sirolimus—MTOR—Signaling Pathways—AKT1—lung cancer	1.02e-06	8.24e-06	CbGpPWpGaD
Sirolimus—CYP3A7—Metabolism—AKT1—lung cancer	9.65e-07	7.78e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—APOA1—lung cancer	9.31e-07	7.51e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PTEN—lung cancer	9.13e-07	7.36e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—EP300—lung cancer	8.71e-07	7.02e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—PIK3CA—lung cancer	8.54e-07	6.89e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CG—lung cancer	8.5e-07	6.85e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—POMC—lung cancer	8.09e-07	6.52e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—CREBBP—lung cancer	7.88e-07	6.35e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CD—lung cancer	7.47e-07	6.02e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—ALB—lung cancer	7.37e-07	5.95e-06	CbGpPWpGaD
Sirolimus—CYP3A5—Metabolism—AKT1—lung cancer	6.97e-07	5.62e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CB—lung cancer	6.51e-07	5.25e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTGS2—lung cancer	6.45e-07	5.2e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—PIK3CA—lung cancer	6.44e-07	5.2e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PTEN—lung cancer	5.63e-07	4.54e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—EP300—lung cancer	5.37e-07	4.33e-06	CbGpPWpGaD
Sirolimus—ABCB1—Metabolism—AKT1—lung cancer	5.26e-07	4.24e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—PIK3CA—lung cancer	3.97e-07	3.2e-06	CbGpPWpGaD
Sirolimus—CYP3A4—Metabolism—AKT1—lung cancer	3.24e-07	2.62e-06	CbGpPWpGaD
